Abstract: The present invention relates to an amphiphilic peptide capable of promoting target miRNA production and a method for regulating the production of target miRNA using the same. In detail, the amphiphilic peptide of the present invention binds strongly and specifically to hairpin-shaped target miRNA. The specific binding affinity induces the Dicer enzyme activity, therefore specifically increase the production of target miRNA. The present invention can be effectively used for regulating the amount of target miRNA produced in vivo, for the study of miRNA functions and for producing therapeutic drug for target miRNA related disease.

Abstract: The present invention provides high throughput assays for TRPM7 activity. The present invention encompasses methods and compositions for screening a sample for inhibitors of TRPM7, including methods and compositions for competitive high throughput assays.

Abstract: The present invention provides a method of inhibiting survival of T helper 1 (Th1) memory cells by contacting or administering a population of Th1 cells with an agent that inhibits CD44 receptor expression or activation. The invention further provides a method of stimulating memory Th1 cell survival comprising contacting or administering Th1 cells with an agent that increases CD44 receptor activation or expression in the cells. The invention additionally provides a method of screening for agents capable of modulating Th1 cell survival.

Abstract: The invention relates to a method for screening compounds for their ability to increase rigidity of red blood cells (RBCs) infected by a protozoan parasite of the genus Plasmodium and in particular by Plasmodium falciparum. The present invention also relates to a method for filtering RBCs that enables retention, in a filtering unit, of RBCs having an abnormal and in particular a decreased deformability, as a surrogate for spleen filtering function. Said method enables in particular isolating and/or detecting Plasmodium-infected RBCs or spherocytes associated with acquired or hereditary spherocytosis from a sample of blood from a patient, or analysing in vitro spleen function of a patient.

Abstract: A method for identifying and selecting chemical entities that contributes to a functional effect in the development of new combinatorial drugs. The combinations of two or more chemical compounds show a synergistic effect. The compounds can be e.g. antibodies, antibiotics, anti-cancer agents, anti-AIDS agents, anti-growth factors, antiviral agents, soluble receptors, cytokines, RNAi's, vaccines and mixtures thereof. The method comprises a) providing n samples each comprising a chemical entity, b) mixing 2 or more of the n samples in all possible combinations, c) subjecting this mixture to a functional assay in order to identify entities contributing to the functional effect. The steps a-c are repeated on the chemical entities from step c which contribute to the functional effect.

Abstract: The present invention relates to isolated nucleic acid sequences that encode human olfactory cyclic nucleotide gated (CNG) channel subunits, and the corresponding polypeptides. The invention further relates to the use of human CNG channels to profile, screen for, and identify compounds that modulate the human olfactory CNG channel. More specifically, the invention relates to the expression of the human olfactory CNG channel in cells, preferably mammalian cells, and the use of these cells in high throughput cell-based assays to identify compounds that enhance or block human olfactory CNG function. Compounds that activate the olfactory CNG channel will enhance smell and can be used to make foods more palatable for individuals with attenuated olfactory function. Conversely, compounds that inhibit the olfactory CNG channel will inhibit smell and can be use to block malodors.

Abstract: The present invention provides methods of screening an agent for an activity in an isolated organ, e.g., eye, from a teleost, e.g., zebrafish. Methods of isolating eyes from zebrafish are provided. Methods of screening an agent for an ocular activity in the isolated eye are provided. Methods of screening an agent for an ocular activity in a model of ocular disease or disorder are provided. Methods of screening an agent for an ocular activity in the isolated eye and for screening the agent for cell death and/or toxic activity in the eye or other organ or tissue are provided. The invention further provides high throughput methods of screening agents for an activity in isolated eyes of zebrafish in multi-well plates.

Abstract: The present invention provides a non-hybrid screening method for the identification and/or isolation of a peptide that is capable of modulating a phenotype in a cell, tissue or organism. For example, the non-hybrid screening method identifies a peptide that is derived from an organism that is unrelated to the cell, tissue or organism. Alternatively, or in addition, the non-hybrid screening method identifies a peptide that is capable of rescuing the cell, tissue or organism from cell death or inducing a cell, tissue or organism to grow. The present invention also provides a non-hybrid screening method for identifying a peptide that is useful for treating a disease and/or disorder.

Abstract: The present invention provides for use of poly-D/L-lysine (PLL) to control the growth of neural cells in vitro and in vivo. The invention describes the activity of defined PLL lines on neural cells and the ability to use the compound to control the direction and rate of growth of neurites on solid substrates. High-throughput screening assays are provided as are medical devices and therapies for treatment of neuronal injury or malfunction.

Abstract: The invention enables high-throughput screening of compounds in living systems to detect unanticipated or unintended biological actions. The invention also allows for screening, detection, and confirmation of new indications for approved drugs. Screening and detection of toxic effects of compounds also can be achieved by using the methods of the invention. The methods comprise administering isotope-labeled substrates to a living system so that the label is incorporated into molecules in a manner that reveals flux rates through metabolic pathways thought to be involved in a disease. Comparisons between living systems exposed to compounds and living systems not so exposed reveals the effects of the compounds on the flux rates through the metabolic pathways. Combinations or mixtures of compounds can be systematically screened to detect unanticipated or unintended biological actions, including synergistic actions, in the same manner.

Abstract: The field of the invention refers to chimeric Virus Like Particles (VLP) derived from Birnavirus chimeric VP2 protein. In particular, the invention refers to chimeric VP2 fusion proteins which incorporate insertions and/or substitutions with one or more amino acids or particular peptide of interest while maintaining the capacity to assemble in the form of VLP. The invention identifies particular insertion and/or substitutions sites within VP2 P loop regions and outside said P loop regions. The invention also incorporates methods for the identification of preferred insertion and substitution sites within VP2 for the incorporation of particular amino acids and peptides of interest. The resulting chimeric VLP are of interest in the design of therapeutic and prophylactic vaccines as well as in the design of drug delivery systems, carriers for DNA and RNA in gene therapy, as targeted agents, in the development of antitoxins, and as diagnostic reagents.

Abstract: Novel compounds comprising a guanidine-rich head covalently coupled to one or more oligonucleotide antisense sequences which are useful to modulate blood coagulation by affecting the expression of integrin ?IIb or ?3 are described herein. This invention also includes pharmaceutical compositions containing these compounds, with or without other therapeutic agents, and to methods of using these compounds as inhibitor of platelet aggregation, as thrombolytics, and/or for the treatment of other thromboembolic disorders. Vivo-MOs, which include eight guanidine groups dendrimerically arranged in the guanidine-rich head and two synthetic antisense morpholino oligonucleotides, are representative compounds of the present invention.

Abstract: The invention is directed to a three-dimensional cell culture array comprising spatially-separated matrices attached to a solid support, wherein a plurality of said matrices encapsulate cells transfected with nucleic acids, method for the preparation of the array and methods reducing the expression of a target gene.

Abstract: A method comprising transforming Schizosaccharomyces pombe with a deletion cassette, constructed by four-round serial PCR, block PCR or total gene synthesis, containing a homologous recombination site is provided for preparing gene-targeted heterozygous deletion Schizosaccharomyces pombe. Also provided are gene-targeted hetero2ygous deletion Schizosaccharomyces pombe mutants prepared by the method, and a library of gene-targeted heterozygous deletion Schizosaccharomyces pombe mutants. Further, the library is useful in constructing a method and a kit for screening a drug's modes of action.

Abstract: The present invention comprises compounds, compositions and methods of use for sensitizing cancer cells, tumors, neoplasms, and malignancies to the effects of ionizing radiation used in the treatment of cancer. The invention further comprises a method of identifying novel radiosensitizing compounds.

Abstract: The invention provides for a method for screening compounds that bind to and modulate the hair-specific G-protein coupled receptor, P2RY5. The invention further provides for methods for controlling hair growth by administering a P2RY5 modulating compound to a subject.

Abstract: This invention relates to a method of screening arrays of polymers having pre-determined surface energies. The polymer arrays of the present invention can be used to screen for microorganism adherence. More specifically the arrays can be used to screen for adherence of particular bacteria or fungi to particular polymers in the array. Furthermore, this invention relates to a method combining in-situ polymer synthesis with physico-chemical characterisation of the resulting polymer array and subsequent biological assays of bacterial or fungal adherence. This allows for high throughput screening and characterisation of candidate polymers which are not susceptible to bacterial or fungal adherence or which can be used to support bacterial or fungal adherence where such is required. The arrays can also be used to screen for inhibition or promotion of biofilm formation.

Abstract: The present invention relates to solution microarrays. In particular, the present invention relates to an aqueous 2-phase system for solution microarrays and uses thereof. Additional embodiments are described herein.

Abstract: The present invention is concerned with the provision of screening assays.

Abstract: The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.

Abstract: The present invention relates to the use of genes differentially expressed in benign thyroid lesions and malignant thyroid lesions for the diagnosis and staging of thyroid cancer.

Abstract: The invention relates to a method for preparing polyepitope chimeric gene vaccines, designated as Epitopes Assemble Library Immunization (EALI). It involves the construction of expression libraries of polyepitope chimeric genes with different sizes and lengths using gene shuffling and random assembly so as to screen polyepitope chimeric gene vaccines. Immunization of the body with the gene libraries of the invention results in the induction of high level of specific antibodies and specific types of cytokines, and protection on the body.

Abstract: An improved process to create an arbitrarily large number of distinguishable particles allows more flexibility in experimental design and related efficiencies of scale. Novel enhanced tracers, for example, Shape Encoded Particles (SEP's) function as indicator means, such as probe-carriers in massively multiplexed assays. Shape encoded identity provides an elegantly simple tracking mechanism, whereby binding/reaction probes coupled to SEP's surfaces can be monitored, viewed, imaged or otherwise utilized leveraging off of the generation of millions of distinct, for example, approximately 100×100×10 micron squared silicon flakes fabricated using conventional MEMS techniques. Plethoric related applications, and contemplated strategies for benefiting from the novel enhanced SEP's and their respective enabling technologies are disclosed, ranging from pearl cultering seed elements to uniquely identify resulting jewelry pieces to an improved parallel stem cell differentiation screening assays.

Abstract: The present invention relates to a method for selecting a suitable expression construct from a plurality of expression constructs for optimizing the production of a protein or a fragment thereof in a host cell, a method for the production of proteins or fragment thereof using the selected expression vector, to novel human embryonic kidney cells that are deficient in N-acetyl-glucosaminyltransferase I and stably transfected with EBNA (HEK 293E GnTI?cells) that are well suitable for use in the said method, in particular for the production of proteins or protein fragments that are suitable for X-ray studies. The invention also relates to a method to produce HEK 293E GnTI? cells and a method to confer to HEK293E GnTI? cells, the capacity to grow in suspension and to a method to confer to HEK293E GnTI? cells, the capacity to grow in serum free medium. The invention also relates to a kit comprising different vectors suitable for use of the above method for the production of proteins or protein fragments.

Abstract: The phosphorylation status of the BAD protein is a determinant of ovarian cancer cell responsiveness to platinum chemotherapy. Indirect manipulation of BAD phosphorylation status influences cisplatin sensitivity. BAD phosphorylation represents a biomarker that predicts platinum sensitivity and is a therapeutic target to increase platinum sensitivity. The methods employ phospho-specific antibody against a particular amino acid residue or site. Phospho-specific protein characterization methods include immunohistochemical (IHC), flow cytometric, immunofluorescent, capture-and-detection, or reversed phase assay.

Abstract: The present invention relates to methods for modulating the activity of one or more Vps10p-domain receptors selected from the group consisting of Sortilin, SorLA, SorCS1, SorCS2 and SorCS3, in an animal and methods for preparation of a medicament for the treatment of abnormal plasma lipid concentrations and associated diseases and/or disorders. The modulation is carried out by inhibiting or promoting the binding of ligands to the Vps10p-domain receptor. In vitro and in vivo methods for screening for agents capable of modulation of said Vps10p-domain receptor activity are also provided. The invention furthermore relates to methods of altering expression of said receptors in vivo.

Abstract: High-throughput methods are provided for quantitatively measuring the modulation of heat shock protein (HSP) expression in a cell by exposing the cell to at least one stress and measuring cellular stress responses. High-throughput methods for identifying modulators (activators or inhibitors) of HSP or HSF expression in a cell by treating the cell with an agent, such as a compound or composition, exposing the cell to a stress, and measuring responses of the cell to the stress in the presence or absence of the agent are also provided. Devices useful in performing high-throughput methods of the invention, and modulators identified using such methods, are also provided.

Abstract: A method for increasing efficiency of germplasm screening for transformability may include providing a plurality of lines of plant target tissue to be transformed, characterizing each of the lines to provide characterization data, the characterization data comprises DNA or nucleic acid delivery technique response data and tissue culture response data, eliminating one or more of the plurality of lines based on the characterization data without performing transformation of the plurality of lines, such that a subset of the plurality of lines remains, and performing transformation experiments on the subset of the plurality of lines. The method may also include selecting a DNA or nucleic acid delivery technique protocol and a tissue culture protocol prior to the characterization.

Abstract: Embodiments of the present disclosure include methods for identifying a compound or compounds useful as therapeutic agents in the treatment of paramyxovirus infections, compounds for the treatment of measles, and high throughput screening methods for identifying compounds capable of inhibiting the proliferation of a paramyxovirus.

Abstract: The invention includes compositions comprising a S. cerevisiae yeast library, and methods of identifying an epigenetic marker for the diagnosis of infertility or a disorder associated with gametogenesis in an individual.

Abstract: The present invention provides cellular screening substrata which can be formed in simple processing steps. The cellular screening substrata can be formed which are characterized in that plural cellular screening substances are positioned and immobilized at predetermined positions on a base by micro-droplet discharging means, and plural areas having different cellular screening functions are formed thereon.

Abstract: The present invention provides compositions and methods to assess the state of a reverse cholesterol transport (RCT). In one aspect of the invention provides methods, compositions and kits for diagnosing a subject with deficient reverse cholesterol transport (RCT). In another aspect, the present invention provides a method of identifying responders to RCT treatment. In yet another aspect, the present invention provides a method of treating a subject with RCT deficiency. Also provided by the present invention is a method for drug screening and/or assessing risk of toxicity associated with RCT treatments.

Abstract: The invention provides methods for treating and preventing a neurodegenerative disease associated with aberrant protein aggregation by modulating the expression and/or activity of XBP-1, IRE-1 alpha, and/or EDEM. The present invention also pertains to methods for identifying compounds that modulate the expression and/or activity of XBP-1, 1RE-1 alpha, and/or EDEM. The present invention further provides methods for determining whether a subject is at risk of developing or has developed a neurodegenerative disease associated with aberrant protein aggregation.

Abstract: The invention provides high throughput screening methodologies for identifying agents that can modulate Epithelial-Mesenchymal Transition (EMT) and/or Mesenchymal-Epithelial Transition (MET) phenotypes of a cell, uses of such agents and methods of identifying a patient that is likely to respond or unlikely to respond to treatment with such agents.

Abstract: Provided are a mast cell degranulation control agent, a diagnostic agent or therapeutic agent for a disease resulting from mast cell degranulation control, a method of controlling mast cell degranulation, and a screening method for a mast cell degranulation control agent, all of which involve the use of a nucleic acid and the like. These are useful in the diagnosis or treatment of a disease resulting from mast cell degranulation control.

Abstract: Provided is a method for high through-put screening for physiologic alterations in an altered teleost displaying a phenotype that is characteristic of the alteration and different from a wild-type, unaltered, matched teleost, comprising the steps of contacting the teleost displaying a genetically-inherited or chemically-induced phenotype with at least one test compound for a sufficient time and under suitable conditions to induce a response in the teleost indicative of pharmacological activity of the compound, and detecting and comparing the response with that of a matched, untreated, control, wherein a change in the teleost signal that is different from that of the control, indicates an altered phenotype and pharmacological activity of the at least one test compound. Further provided are the compounds identified by this method, the zebrafish having an altered phenotype resulting from treatment in accordance with these methods, and kits for facilitating the high through-put screening methods.

Abstract: The present invention refers to human EGLN2 variants having at position 58 of the amino acid sequence a serine or a leucine and their use in the prevention or treatment of thromboembolic or coronary heart diseases, in particular stroke, prolonged reversible ischemic neurological deficit (PRIND), transitoric ischemic attack (TIA), myocardial infarction and/or early myocardial infarction.

Abstract: The present invention relates to the modulation of quorum sensing mechanisms in a microorganism for the purpose of exploiting the fermentation capabilities of the microorganism.

Abstract: A method for detecting apoptosis of embryonic stages of parasitic helminthes. The method comprises isolating of intra uterine embryonic stages from an adult female parasite. The embryonic stages are cultured in vitro and treated. The said embryonic stages are subjected to flow cytometric analysis. An assay for apoptosis is performed being capable of high throughput screening and identification of compounds having apoptogenic activity towards the embryonic stages of helminthic parasites.

Abstract: The present invention provides for monitoring of NF-?B-associated inflammation in mice undergoing Id-driven autoimmune disease. The mice are triple transgenic mice expressing both Id+ B cells and Id-specific CD4+ T cells as well as a luciferase reporter transgene under NF-?B control. NF-?B activation and nuclear translocation of NF-?B, luciferase activity are repeatedly monitored in intact mice by whole body bioluminescence imaging. Results are corroborated at the cellular level by detection of luciferase protein expression in single cells. The results show that imaging of NF-?B activation permits early detection of subclinical disease as well as tracking of disease development.

Abstract: The present invention provides a method for measuring cellular nascent nucleic acid synthesis by dual pulse labeling of nucleic acid. The first pulse labeling of nucleic acid with a nucleoside analog allows establishment of a baseline nucleic acid synthesis rate. Pulse labeling of the nucleic acid with a second nucleoside analog then allows measurement of any changes to nucleic acid synthesis. The nucleic acid synthesis can be measured as cell proliferation, DNA, or gene expression, RNA. This method does not require a potentially artifact-inducing intermediary wash step between pulse labels. Additionally, this method may be used to screen compounds for their affect on cellular proliferation by treating cells or an organism with the test compound simultaneous to or before treatment with a competitive nucleoside analog.

Abstract: Provided herein are methods of detecting responses of bio-artificial tissues to agents by performing assays using three-dimensional bio-artificial tissues. The methods are adaptable to high-throughput platforms.

Abstract: Methods and compositions are provided for the preparation of insecticidal compositions.

Abstract: The present invention provides for identification and use of small molecules to induce pluripotency in mammalian cells as well as other methods of inducing pluripotency.

Abstract: The present invention relates to serine hydroxymethyltransferase (E.C. 2.1.2.1) as novel target for herbicides, and to nucleic acid sequences encoding a polypeptide with the biological activity of a serine hydroxymethyltransferase, which, when not present, bring about growth retardation symptoms and chlorotic leaves, comprising the nucleic acid sequence SEQ ID No:3, and functional equivalents of the abovementioned nucleic acid sequence or the nucleic acid sequence SEQ ID NO:7 and functional equivalents of the abovementioned nucleic acid sequence. Moreover, the present invention relates to the use of the abovementioned nucleic acid sequences, of functional analogs of the SEQ ID NO:3 or SEQ ID NO:7 or of polypeptides encoded by one of the abovementioned nucleic acid sequences in a method for identifying herbicidally active compounds which inhibit serine hydroxymethyltransferases, and to the use of these compounds which have been identified by the method as herbicides.

Abstract: The invention provides methods for detecting virus production, determining frequency and identity of HIV reservoirs, or evaluating gene expression on a single-cell basis using microengraving and RT-PCR.

Abstract: The present invention relates to systems and methods for testing kinase inhibition using an array of substrates, in particular protein kinase substrates, preferably immobilized on a porous matrix. More particularly, the method provides kinase inhibition profiles of kinase inhibitors using phosphorylation patterns. The present invention can therefore be used to predict the response of cells, tissues, organs and/or warm-blooded animals to a drug, to determine the clinical outcome of a drug therapy and for diagnostical and prognostical purposes.

Abstract: The present invention relates to a method for screening and identifying compounds that modulate the activity tRNA splicing endonuclease. In particular, the invention provides assays for the identification of compounds that inhibit animalia tRNA splicing endonuclease. The methods of the present invention provide a simple, sensitive assay for high-throughput screening of libraries of compounds to identify pharmaceutical leads useful for treating and/or preventing cancer.

Abstract: The invention provides cryopreserved compositions of cells, wherein the compositions are advantageously in the form of self-sustaining bodies that can be individually handled and combined independently of a container, allowing for easy customization of the eventual pooled preparation. The invention also provides pre-pooled stacks of the self-sustaining cryopreserved compositions for eventual thawing to produce pooled preparations of cells. A mold and methods for forming the self-sustaining bodies are also provided. The invention is also concerned with methods of forming pooled preparations of cells using single-cryopreserved compositions of cells.

Abstract: The present invention relates to compounds that modulate the replication of negative-sense, single-stranded RNA viruses, such as influenza virus, and the use of such compounds. The invention relates to methods for increasing the titer of negative-sense, single-stranded RNA viruses, such as influenza virus, in substrates for virus propagation (e.g., tissue culture). The invention also relates to the use of compounds that decrease virus replication as antiviral agents. The invention further relates to methods for identifying compounds that modulate the replication of negative-sense, single-stranded RNA viruses, in particular, influenza virus.